The tumor-associated carbonic anhydrase (CA, EC 4.2.1.1) isozyme CA IX is highly overexpressed in many cancer types via the hypoxia inducible factor-1 alpha. (HIF-1 alpha) cascade. Hypoxic tumors expressing CA IX show...

Drugs that bind to the colchicine binding site of tubulin and induce tubulin depolymerization hold promise as antitumor drugs through their ability to induce cell cycle arrest and to kill cancer cells through apoptosi...

Cancer remains a leading cause of death globally, including in developing countries. In spite of the introduction of several new drugs to the anti-cancer arsenal in recent years, including monoclonal antibodies and se...

The tumor suppressor p53 is frequently inactivated in a wide variety of cancers and point mutations or deletions of the p53 gene are associated with poor prognosis in cancer. About half of all human tumors carry wildt...

The enzymes involved in the synthesis of steroids are very interesting therapeutic targets. By reducing the levels of androgens and estrogens that stimulate the proliferation of cancer cells, a potent and selective in...

The evolutionarily conserved Notch signaling pathway controls diverse events such as cell fate determination, proliferation, apoptosis, and stem cell maintenance. Dysregulation of this pathway has been implicated as a...

Anti-angiogenesis is a promising strategy for the treatment of cancer. Integrins, consisting of two noncovalently bound transmembrane alpha and beta subunits, are an important molecular family involved in tumor angiog...

Although traditional chemotherapeutic agents have saved thousands of lives over the years and delayed tumor progression, they have limited efficacy due to toxicity and lack of tumor cell selectivity. Recently some of ...

Epidermal growth factor receptor (EGFR) inhibitors have introduced the concept of targeted therapy to the treatment of non-small cell lung cancer (NSCLC). These agents appear most effective in patients with tumors tha...